BiotechTube
OncoDiag

OncoDiag

Paris, France· Est.
oncodiag.fr
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

OncoDiag is a private, French diagnostics company developing a portfolio of non-invasive tests targeting major cancers including bladder, prostate, and colorectal. The company's lead product, Urodiag®, is already CE-marked for bladder cancer surveillance, positioning it in the early revenue stage. With a management team possessing decades of experience in diagnostics and oncology, and supported by a key scientific advisory board, OncoDiag aims to address significant unmet needs in cancer screening and monitoring through liquid biopsy and tissue-based approaches.

Bladder CancerProstate CancerColorectal Cancer

Technology Platform

Multi-modal diagnostic assay development utilizing urine, blood, and tissue samples for non-invasive cancer detection and monitoring.

Opportunities

The high global incidence of bladder, prostate, and colorectal cancers, combined with limitations and patient burden of current invasive screening/surveillance methods (cystoscopy, colonoscopy), creates a significant demand for validated non-invasive alternatives.
Favorable trends towards personalized medicine and active surveillance protocols, especially in prostate cancer, further support the adoption of prognostic tests like ProstaScore®.

Risk Factors

Key risks include the failure of pipeline products to demonstrate sufficient clinical utility and specificity in validation studies, challenges in securing reimbursement and clinical guideline adoption for its commercialized product, and intense competition from larger diagnostics firms and well-funded startups in the liquid biopsy space.

Competitive Landscape

OncoDiag operates in the highly competitive field of non-invasive cancer diagnostics. It faces competition from established urine markers for bladder cancer (e.g., NMP22, UroVysion), numerous liquid biopsy companies developing blood-based tests for prostate and colorectal cancer (e.g., Guardant Health, Exact Sciences, Freenome), and large IVD conglomerates with extensive R&D and commercial reach.

More companies in Diagnostics & Precision Medicine →More companies in France →